Jay Shepard currently serves as an Executive Partner at Sofinnova Ventures. He has over 30 years experience in the pharmaceutical, biotechnology and drug delivery arenas. Jay was President and CEO of NextWave Pharmaceutical, a pediatric-focused therapeutics company. NextWave was acquired in late 2012 by Pfizer. From 2008-2010 he was an Executive in Residence at Sofinnova Ventures. Prior to that, Jay was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen. He then helped with the Ilypsa spin-out company, Relypsa, serving as interim President and CEO. Before Ilypsa, Jay served as Vice President, Commercial Operations at Telik. He was also Vice President in the Commercial Operations group at Alza Pharmaceuticals, having held leadership roles of increasing responsibility in its establishment, operation and commercial presence. Alza was acquired by Johnson & Johnson in late 2001. Jay is currently a board member of Bullet Biotechnologies, Marinus Pharmaceuticals, Durect Corporation and the Santa Clara University Entrepreneurial School. Jay holds a BS in Business Administration from the University of Arizona.
Jeff Cleland has 20 years of industry experience in research and development, including more than a decade at Genentech, Inc. He held executive management positions at BaroFold, Novacea, and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. His experience in start-ups includes major roles in obtaining more than $70M of Series A through C venture capital as well as an exit via IPO. Jeff also runs his own pharmaceutical and biotechnology consulting group for numerous start-ups and venture firms. While at Genentech, Jeff served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, and Omnitarg®. He holds a BS degree in Chemical Engineering from the University of California, Davis and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Jeff has authored more than 100 articles and four books, and holds several issued patents.
Ed Jennings, a biotechnology industry consultant, had a key leadership role in Genentech's commercialization of the first recombinant human growth hormone. During his 15 years at Genentech he also held a number of senior-level positions including Vice President of Sales, Marketing, and Corporate Development. Most recently, Ed served as President, Chief Executive Officer and Board Member of Angiogenix, Inc., directing all scientific and business activities at the cardiovascular biotechnology startup company. Previously, he was the Chief Commercialization Officer at Pain Therapeutics, where he was responsible for the company's business development, marketing and sales functions, as well as leading the development of the company's commercialization strategy. Ed began his career in the pharmaceutical industry at Bristol Myers, where he managed sales and marketing functions for more than a decade.
Shahzad Malik joined Advent in 1999. He came with a strong grounding in science and clinical medicine. Prior to joining Advent he spent six years practising medicine, before joining the London office of management consultants McKinsey & Company. Here he served international clients in the Healthcare and Investment Banking sectors. During his time with Advent he has been actively involved with numerous investments in Europe and the United States in the biopharmaceutical and medical device arenas. Shahzad gained an MA from Oxford University, and a MD from Cambridge University. He subsequently specialised in interventional cardiology, whilst also pursuing research interests in heart muscle disorders both in the clinic and basic science laboratory.
Dr. Sun joined Fund I in 2002 and currently serves as a Partner. Previously, Dr. Sun was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania. Dr. Sun received his M.D. from Temple University School of Medicine with A.O.A. honors. He received his M.B.A. from The Wharton School at the University of Pennsylvania, and his B.S. in Electrical Engineering from Cornell University. In addition, he is Board Certified in Internal Medicine.